Insider Selling: Invivyd (NASDAQ:IVVD) Insider Sells $21,678.80 in Stock

Key Points

• Insider Jill Andersen sold 33,352 shares of Invivyd stock on August 18 for $21,678.80, reducing her stake by nearly 20%.
• Invivyd's stock recently traded down 1.7% to $0.5710, with a market cap of approximately $68.60 million.
• The company reported $11.79 million in revenue for the last quarter, missing analyst estimates of $23.16 million and posting a negative earnings per share of ($0.12).

Invivyd, Inc. (NASDAQ:IVVD - Get Free Report) insider Jill Andersen sold 33,352 shares of Invivyd stock in a transaction dated Monday, August 18th. The stock was sold at an average price of $0.65, for a total transaction of $21,678.80. Following the sale, the insider directly owned 133,848 shares of the company's stock, valued at $87,001.20. The trade was a 19.95% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink.

Jill Andersen also recently made the following trade(s):

• On Tuesday, August 19th, Jill Andersen sold 49,402 shares of Invivyd stock. The stock was sold at an average price of $0.57, for a total transaction of $28,159.14.

Invivyd Stock Down 1.7%

Shares of Invivyd stock traded down $0.0101 on Tuesday, hitting $0.5710. The stock had a trading volume of 1,690,635 shares, compared to its average volume of 850,421. The stock has a market cap of $68.60 million, a price-to-earnings ratio of -0.62 and a beta of 0.51. Invivyd, Inc. has a twelve month low of $0.3546 and a twelve month high of $2.74. The business's 50 day moving average is $0.75 and its two-hundred day moving average is $0.84.

Invivyd (NASDAQ:IVVD - Get Free Report) last posted its earnings results on Thursday, August 14th. The company reported ($0.12) earnings per share for the quarter, missing analysts' consensus estimates of ($0.04) by ($0.08). Invivyd had a negative return on equity of 177.89% and a negative net margin of 238.33%.The firm had revenue of $11.79 million for the quarter, compared to analyst estimates of $23.16 million. As a group, equities analysts predict that Invivyd, Inc. will post -1.64 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the stock. D. Boral Capital lowered their target price on shares of Invivyd from $9.00 to $3.00 and set a "buy" rating on the stock in a report on Friday. HC Wainwright restated a "buy" rating and set a $5.00 price objective on shares of Invivyd in a research note on Thursday, June 26th. One investment analyst has rated the stock with a Strong Buy rating and three have issued a Buy rating to the company's stock. According to data from MarketBeat, Invivyd presently has an average rating of "Buy" and a consensus price target of $3.85.

Hedge Funds Weigh In On Invivyd

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Catalyst Funds Management Pty Ltd acquired a new position in shares of Invivyd during the second quarter worth $27,000. Vanguard Personalized Indexing Management LLC grew its position in Invivyd by 238.6% during the 2nd quarter. Vanguard Personalized Indexing Management LLC now owns 39,941 shares of the company's stock worth $29,000 after acquiring an additional 28,146 shares during the last quarter. Jane Street Group LLC grew its position in Invivyd by 290.5% during the 4th quarter. Jane Street Group LLC now owns 117,432 shares of the company's stock worth $52,000 after acquiring an additional 87,358 shares during the last quarter. Barclays PLC increased its holdings in Invivyd by 7.8% in the 4th quarter. Barclays PLC now owns 127,180 shares of the company's stock worth $56,000 after purchasing an additional 9,207 shares in the last quarter. Finally, Nuveen LLC bought a new position in Invivyd in the first quarter valued at about $65,000. Institutional investors own 70.36% of the company's stock.

Invivyd Company Profile

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.